Inclusion Criteria:

          -  Metastasized or locally advanced incurable triple negative breast cancer; patients
             with stage IV at diagnosis are eligible as well. If the primary lesion is the only
             measurable lesion according to RECIST criteria, every locoregional treatment must be
             mentioned to the investigators.

          -  Histologically confirmed triple negative breast cancer (ER: < 10% nuclear staining of
             tumor cells on IHC; HER2: either score 0 or 1 at immunohistochemistry or negative at
             in situ hybridization [CISH or FISH] in case of score 2 or 3 on IHC)

          -  Histological confirmation of triple negative breast cancer of a metastatic lesion is
             recommended

          -  Histological or cytological confirmation of metastatic breast cancer is required in
             case of normal CA 15.3 levels

          -  Primary tumor or metastasis tissue (10 x10 μm blank slides FFPE tumor material) sent
             to NKI-AVL for BRCA-like testing

          -  Pretreatment histological biopsy of a metastatic lesion for the translational research
             questions (tumor tissue from bone metastases cannot be used).

          -  No previous cytotoxic therapy for metastatic disease

          -  Disease-free interval of at least 12 months after completion of adjuvant paclitaxel or
             platinum compound therapy

          -  Disease-free interval of at least 6 months after completion of adjuvant docetaxel

          -  Measurable disease according to RECIST v1.1

          -  WHO performance status of 0 or 1

          -  Adequate bone marrow function: neutrophils ≥ 1.5 x 10E9 cells/l, platelets ≥100 x 10E9
             cells/l, Hb ≥ 6.2 mmol/l.

          -  Normal liver function: bilirubin < 1.5 x upper limit of the normal range (ULN);
             alkaline phosphatase < 2.5 x ULN (< 5 x ULN in case of liver metastases, and < 7 x ULN
             in case of bone metastases); transaminases (ASAT/ALAT) < 2.5 x ULN (and < 5 x ULN in
             case of liver metastases).

          -  Normal renal function:

             > calculated (Cockcroft-Gault) or measured creatinine clearance > 50 mL/min

          -  INR < 1.5 and APTT normal, unless patient is on stable anti-coagulant treatment for at
             least two weeks with a low molecular weight heparin or coumarin, then an INR within
             the target range (usually between 2 and 3) is allowed.

          -  Written informed consent

        Exclusion Criteria:

          -  Receptor conversion to hormone receptor positive (defined as >= 10% positive ER or PgR
             tumor cells) or HER2 positive

          -  Another cancer except basal-cell carcinoma of the skin or in situ cervical cancer
             within the previous 5 years

          -  Other antitumor therapy within the previous 21 days

          -  Radiotherapy with palliative intent within the previous 7 days before randomization.

          -  Known CNS disease except for treated brain metastases.

          -  Uncontrolled serious medical or psychiatric illness

          -  Pre-existing peripheral neuropathy > grade 1 (NCI-CTC AE (version 4.03)) at inclusion

          -  Severe infection within 4 weeks prior to randomization

          -  received antibiotocs within 2 weeks prior to cycle 1, day 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to randomization or anticipation of need for major surgical procedure during the
             course of the study

          -  New York Heart Association Class II or greater congestive heart failure. LVEF by MUGA,
             ultrasound or MRI must be ≥ 50% and should be performed within 4 weeks prior to
             randomization if cardiac failure is suspected.

          -  History of myocardial infarction or unstable angina within 6 months prior to
             randomization

          -  History of myocardial infarction or unstable angina or unstable arrhytmias within 3
             months prior to randomization

        futher criteria, see protocol